Randomized trial demonstrates improved β-cell proliferation in type 1 diabetes, suggesting a new therapeutic approach.
Key Points
This research investigates the efficacy of lacritin-derived peptide N-104 in promoting β-cell regeneration and reducing inflammatory damage in type 1 diabetes.
Cultured human pancreatic slices ex vivo with pro-inflammatory cytokines.
Performed multichannel immunofluorescence to assess β-cell proliferation and inflammatory signaling.
Conducted supporting analyses including GSIS, viability assays, and treatment in NOD mouse models.
Human plasma from type 1 diabetics lacked active lacritin (p<0.001).
N-104 increased β-cell proliferation by 3.6-fold and reduced inflammatory stress.
N-104-pretreated islets restored normoglycemia in treated mice for ≥23 weeks.